NICE rules out NHS prescription of fingolimod for multiple sclerosis

D Cohen - 2011 - bmj.com
D Cohen
2011bmj.com
The only oral drug for the treatment of a particular type of multiple sclerosis should not be
prescribed on the NHS in England and Wales, draft guidance from the National Institute for
Health and Clinical Excellence has said.Despite the excitement earlier this year over the
launch of the drug, fingolimod, a sphingosine-1-phosphate receptor, NICE has announced
in provisional draft guidance that not only is the drug not cost effective but there was a lack of
appropriate data.
The only oral drug for the treatment of a particular type of multiple sclerosis should not be prescribed on the NHS in England and Wales, draft guidance from the National Institute for Health and Clinical Excellence has said.
Despite the excitement earlier this year over the launch of the drug, fingolimod, a sphingosine-1-phosphate receptor, NICE has announced in provisional draft guidance that not only is the drug not cost effective but there was a lack of appropriate data.
bmj.com